Show simple item record

dc.contributor.authorAnpalakhan, S.
dc.contributor.authorHuddar, Prerana
dc.contributor.authorBehrouzi, Roya
dc.contributor.authorSignori, A.
dc.contributor.authorCave, J.
dc.contributor.authorComins, C.
dc.contributor.authorCortellini, A.
dc.contributor.authorAddeo, A.
dc.contributor.authorEscriu, C.
dc.contributor.authorMcKenzie, H.
dc.contributor.authorBarone, G.
dc.contributor.authorMurray, L.
dc.contributor.authorBhatnagar, G.
dc.contributor.authorPinato, D. J.
dc.contributor.authorOttensmeier, C.
dc.contributor.authorGomes, Fabio
dc.contributor.authorBanna, G. L.
dc.date.accessioned2023-02-23T15:17:15Z
dc.date.available2023-02-23T15:17:15Z
dc.date.issued2023en
dc.identifier.citationAnpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, et al. The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. International journal of molecular sciences. 2023 Jan 16;24(2). PubMed PMID: 36675262. Pubmed Central PMCID: PMC9867035. Epub 2023/01/22. eng.en
dc.identifier.pmid36675262en
dc.identifier.doi10.3390/ijms24021746en
dc.identifier.urihttp://hdl.handle.net/10541/626017
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3390/ijms24021746en
dc.titleThe effects of GCSF primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy: a sub-analysis of the Spinnaker studyen
dc.typeArticleen
dc.contributor.departmentPortsmouth Hospitals University NHS Trust, Portsmouth PO6 3LY, UKen
dc.identifier.journalInternational Journal of Molecular Sciencesen
dc.description.noteen]
refterms.dateFOA2023-03-06T12:32:31Z


Files in this item

Thumbnail
Name:
36675262.pdf
Size:
658.2Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record